Highlights
• Convatec raised its FY26 group organic Revenue growth guidance to 6.25–7.0%, up from 5.5–6.5% previously.
• Year-to-date organic revenue grew 6.6% excluding InnovaMatrix and 3.7% including it, with reported revenue up 4.8%.
• Infusion Care delivered double-digit growth in the second half, while Continence Care grew at a mid-to-high single-digit rate.
• The medical products group reiterated double-digit adjusted EPS growth and a buyback of about $200m.
What does a guidance upgrade two months before year-end tell investors? For Convatec (LSE:CTEC), the answer arrived in its 10-month trading update, which raised the bottom and top of its 2026 organic revenue growth range. The medical products specialist also pointed to improved trading in the second half, bringing the healthcare stock back into view among LSE stocks.
Convatec raises FY26 organic revenue guidance
The headline change is to full-year guidance. Convatec (LSE:CTEC) now expects group organic revenue growth of 6.25% to 7.0% for 2026, up from its earlier range of 5.5% to 6.5%. The company also reiterated its expectation of double-digit growth in adjusted earnings per share.
Those numbers matter because organic growth is the yardstick Convatec (LSE:CTEC) uses for its annual targets, so a higher range resets the bar for the full year. Year to date, organic revenue grew 6.6% excluding InnovaMatrix and 3.7% including it. On a reported basis, revenue rose 4.8%. Organic growth excludes currency movements and the effect of acquisitions, while reported growth reflects the figures as stated.
Second-half momentum across the portfolio
According to the update, second-half trading improved. Infusion Care grew at a double-digit rate. Continence Care grew at a mid-to-high single-digit rate.
The company's decision to lift the guidance range came with only two months of the financial year remaining, giving the second-half trends added weight in the full-year picture.
Margins, InnovaMatrix and other financial guidance
Convatec expects an adjusted operating Margin of at least 23% for FY26. The company said that figure absorbs about 65 basis points of foreign exchange headwind and about 90 basis points relating to InnovaMatrix, a wound Biologics product. FY26 revenue from InnovaMatrix is expected to be about $5m.
Other guidance points include total Capital Expenditure at the upper end of $200m to $230m, with growth capex of $135m to $165m. Adjusted net finance expense is expected to be about $75m, and cash conversion of around 90%.
Shareholder returns and key considerations
The share buyback of about $200m remains on track, according to the update. Alongside capital expenditure guidance at the upper end of its range, the programme shows how the company is allocating cash between Investment in the Business and returns to shareholders this year. Buybacks reduce the share count and form part of the group's capital allocation alongside investment in growth.
The considerations flagged in the statement itself are currency movements and the contribution of InnovaMatrix, both of which Convatec quantified in its margin guidance. Investors following UK shares in MedTech can compare those effects with the underlying growth rates. Separating the two helps explain why the reported, organic and margin figures move by different amounts in the same update, and why the company presents organic growth both with and without InnovaMatrix.
Full-year results set the next milestone
With guidance now raised, the full-year results will show where organic growth lands within the new 6.25% to 7.0% range. Shareholders are also likely to watch the final margin figure against the 23% floor, the completion of the buyback, and any commentary on 2027 when the company next reports to the UK stock market.
Why Convatec reports organic growth
Convatec presents its growth in several ways because each one answers a different question. Reported revenue growth, at 4.8% year to date, reflects figures as stated, including currency movements and acquisitions. Organic growth excludes both, which is why it is the yardstick for annual targets. The company also shows organic growth with and without InnovaMatrix, giving readers a way to separate the wound biologics product from the rest of the portfolio, at 3.7% including it and 6.6% excluding it. The raised guidance range of 6.25% to 7.0% applies to the group figure, so the final result will show where growth lands within that band.
Margins and Cash Flow guidance
Alongside the revenue range, Convatec guided to an adjusted Operating Margin of at least 23%, after absorbing about 65 basis points of foreign exchange headwind and about 90 basis points relating to InnovaMatrix. Other guidance covers total capital expenditure at the upper end of $200m to $230m, growth capex of $135m to $165m and adjusted net finance expense of about $75m. Cash conversion is expected to be around 90%, a measure of how much operating profit turns into cash, and the buyback of about $200m remains on track.






Please wait processing your request...